If you suffered losses exceeding $100,000 in AstraZeneca between between February 23, 2022 and December 17, 2024 and would ...

In a report released today, Emily Field from Barclays maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price target of ...

Shares of AstraZeneca PLC AZN slipped 1.77% to £106.30 Tuesday, on what proved to be an all-around poor trading session for ...

AstraZeneca is a company with a turbulent history but, for now, a promising future. We take a look at the company's story, from its creation as a merger of two equals, to its recent major ...

The AstraZeneca PLC ADR AZN slipped 0.55% to $65.37 Tuesday, on what proved to be an all-around mixed trading session for the ...

AstraZeneca has sued a handful of drug companies to protect its cancer treatment drug, Lynparza. The suits, which were filed by attorneys with Gibbons and Williams & Connolly, seek to protect the ...

Synthego, a leading supplier of CRISPR solutions, has entered a strategic licensing agreement with global biopharmaceutical company AstraZeneca. This agreement grants Synthego a global license to ...

Although headquartered in the UK, AstraZeneca is still known as the 'Anglo-Swedish pharma company', having been created from the merger of the British Zeneca and Sweden's Astra in 1999.

AstraZeneca is facing some headwinds related to its operations in China. Still, the company's financial results and pipeline look strong. The stock could deliver solid returns for those who invest ...

NEW YORK, USA - - 14 January 2025 – The highly anticipated Best Places to Work World Rankings for 2024 have been revealed, ...